Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | S100A4 | P26447 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711752 | 0.74 | TGFBR1 (0.38) | RAB9ANPC1TGFBR1CYP1A2NSD2 | |
| SCHEMBL18807016 | 0.72 | CCR1 (0.62) | CCR1CCR8NOS3NOS2TGFBR1 | |
| SCHEMBL15883642 | 0.72 | PIM2 (0.44) | — | |
| SCHEMBL19240430 | 0.71 | S1PR4 (0.34) | — | |
| SCHEMBL18259260 | 0.71 | CCR1 (0.41) | CCR1L3MBTL1RAB9ANPC1CASP3 | |
| SCHEMBL18259430 | 0.71 | CCR1 (0.41) | CCR1L3MBTL1TDP1RAB9ANPC1 | |
| SCHEMBL27997101 | 0.70 | TGFBR1 (0.40) | RAB9ANPC1TGFBR1NSD2G6PD | |
| SCHEMBL21083452 | 0.69 | MAPT (0.45) | L3MBTL1TDP1TGFBR1METAP2S100A4 | |
| SCHEMBL318608 | 0.69 | KDM4E (0.50) | TDP1 | |
| SCHEMBL15894764 | 0.69 | PIM2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112794860-B | Oxazole pyrimidone amide compound or medicinal salt thereof, preparation method and application | 上海肇钰医药科技有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-112794860-A | Oxazole pyrimidone amide compound or medicinal salt thereof, preparation method and application | 上海肇钰医药科技有限公司 | 2021-05-14 | — | — | CN | disclosed |
| EP-2861585-B1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-01-09 | — | — | EP | disclosed |
| CN-104334546-B | Novel ring-substituted N-pyridyl amides as kinase inhibitors | 诺华股份有限公司 | 2017-05-03 | — | — | CN | disclosed |
| WO-2017045615-A1 | PYRIDINE DERIVATIVE PIM KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE PREPARATION | 上海吉铠医药科技有限公司 | 2017-03-23 | — | — | WO | disclosed |
| WO-2017045612-A1 | PYRIMIDINE DERIVATIVE PIM KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE PREPARATION | 上海吉铠医药科技有限公司 | 2017-03-23 | — | — | WO | disclosed |
| WO-2017045616-A1 | ISOTHIAZOLE DERIVATIVE PIM KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE PREPARATION | 上海吉铠医药科技有限公司 | 2017-03-23 | — | — | WO | disclosed |
| CN-106243018-A | A kind of synthetic method of poly-fluorine phenyl pyridine compounds and their | 陕西师范大学 | 2016-12-21 | — | — | CN | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| EP-2344474-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CCR1 2733/4885CCR8 2917/4885L3MBTL1 750/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | CCR1 2733/4885CCR8 2917/4885L3MBTL1 750/4885 |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CCR1 2733/4885CCR8 2917/4885L3MBTL1 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.